Posted by Admin | 9:58 AM

Here are a few reasonable questions I decided to elevate as a post of its own. In the face of the discovery of industry influence over comme...

Labels: ghost writing, ghostwriting, meaningful use final rule, meaningful use stage 2, ONC, regulatory capture, stealth lobbying

Posted by Admin | 6:22 AM

Note: Also see the followup Sept. 5, 2012 post " Was EPIC successful in watering down the Meaningful Use Stage 2 Final Rule? " at ...

Labels: conflicts of interest, Dayton Children's Hospital, EPIC, ghost writing, ghostwriting, meaningful use stage 2, ONC, stealth lobbying, University of Miami

Posted by Admin | 2:12 PM

Before it was abruptly ended by a sudden settlement for $158 million, the trial in Texas of a suit alleging unethical marketing of the drug ...

Labels: conflicts of interest, deception, evidence-based medicine, ghostwriting, intimidation, Johnson and Johnson, key opinion leaders, Risperdal, stealth marketing